Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes

Kim, Yonghyo LU ; Gil, Jeovanis LU ; Pla, Indira LU orcid ; Sanchez, Aniel LU ; Betancourt, Lazaro Hiram LU ; Lee, Boram LU ; Appelqvist, Roger LU ; Ingvar, Christian LU ; Lundgren, Lotta LU and Olsson, Håkan LU orcid , et al. (2020) In Cancers 12(3).
Abstract

Malignant melanoma is among the most aggressive skin cancers and it has among the highest metastatic potentials. Although surgery to remove the primary tumor is the gold standard treatment, once melanoma progresses and metastasizes to the lymph nodes and distal organs, i.e., metastatic melanoma (MM), the usual outcome is decreased survival. To improve survival rates and life span, advanced treatments have focused on the success of targeted therapies in the MAPK pathway that are based on BRAF (BRAF V600E) and MEK. The majority of patients with tumors that have higher expression of BRAF V600E show poorer prognosis than patients with a lower level of the mutated protein. Based on the molecular basis of melanoma, these findings are... (More)

Malignant melanoma is among the most aggressive skin cancers and it has among the highest metastatic potentials. Although surgery to remove the primary tumor is the gold standard treatment, once melanoma progresses and metastasizes to the lymph nodes and distal organs, i.e., metastatic melanoma (MM), the usual outcome is decreased survival. To improve survival rates and life span, advanced treatments have focused on the success of targeted therapies in the MAPK pathway that are based on BRAF (BRAF V600E) and MEK. The majority of patients with tumors that have higher expression of BRAF V600E show poorer prognosis than patients with a lower level of the mutated protein. Based on the molecular basis of melanoma, these findings are supported by distinct tumor phenotypes determined from differences in tumor heterogeneity and protein expression profiles. With these aspects in mind, continued challenges are to: (1) deconvolute the complexity and heterogeneity of MM; (2) identify the signaling pathways involved; and (3) determine protein expression to develop targeted therapies. Here, we provide an overview of the results from protein expression in MM and the link to disease presentation in a variety of tumor phenotypes and how these will overcome the challenges of clinical problems and suggest new promising approaches in metastatic melanoma and cancer therapy.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancers
volume
12
issue
3
article number
767
publisher
MDPI AG
external identifiers
  • scopus:85082880752
  • pmid:32213878
ISSN
2072-6694
DOI
10.3390/cancers12030767
language
English
LU publication?
yes
id
c99b5cca-f900-4571-b9b5-b62b4e707d3b
date added to LUP
2020-04-10 23:07:07
date last changed
2024-04-03 06:19:53
@article{c99b5cca-f900-4571-b9b5-b62b4e707d3b,
  abstract     = {{<p>Malignant melanoma is among the most aggressive skin cancers and it has among the highest metastatic potentials. Although surgery to remove the primary tumor is the gold standard treatment, once melanoma progresses and metastasizes to the lymph nodes and distal organs, i.e., metastatic melanoma (MM), the usual outcome is decreased survival. To improve survival rates and life span, advanced treatments have focused on the success of targeted therapies in the MAPK pathway that are based on BRAF (BRAF V600E) and MEK. The majority of patients with tumors that have higher expression of BRAF V600E show poorer prognosis than patients with a lower level of the mutated protein. Based on the molecular basis of melanoma, these findings are supported by distinct tumor phenotypes determined from differences in tumor heterogeneity and protein expression profiles. With these aspects in mind, continued challenges are to: (1) deconvolute the complexity and heterogeneity of MM; (2) identify the signaling pathways involved; and (3) determine protein expression to develop targeted therapies. Here, we provide an overview of the results from protein expression in MM and the link to disease presentation in a variety of tumor phenotypes and how these will overcome the challenges of clinical problems and suggest new promising approaches in metastatic melanoma and cancer therapy.</p>}},
  author       = {{Kim, Yonghyo and Gil, Jeovanis and Pla, Indira and Sanchez, Aniel and Betancourt, Lazaro Hiram and Lee, Boram and Appelqvist, Roger and Ingvar, Christian and Lundgren, Lotta and Olsson, Håkan and Baldetorp, Bo and Kwon, Ho Jeong and Oskolás, Henriett and Rezeli, Melinda and Doma, Viktoria and Kárpáti, Sarolta and Szasz, A Marcell and Németh, István Balázs and Malm, Johan and Marko-Varga, György}},
  issn         = {{2072-6694}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  publisher    = {{MDPI AG}},
  series       = {{Cancers}},
  title        = {{Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes}},
  url          = {{http://dx.doi.org/10.3390/cancers12030767}},
  doi          = {{10.3390/cancers12030767}},
  volume       = {{12}},
  year         = {{2020}},
}